Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis.

Allergy · 2019 · PMC6590149 · PMID 30488542

Europe PMC DOI

hedged sentence

0.6364

closest p · 12.7× alpha

0.6364

boldest claim

The sentences

did not reach statistical significanceP = 0.6364not close (p > 0.1)

The decrease in ECP in the dupilumab group compared to placebo did not reach statistical significance (−5.82 [4.3] vs −3.07 [4.6] ng/mL; P = 0.6364).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.